Serplulimab plus chemotherapy as first-line treatment for extensive-stage small-cell lung cancer: A cost-effectiveness analysis

Serplulimab plus chemotherapy as first-line treatment for extensive-stage small-cell lung cancer: A cost-effectiveness analysis

IntroductionThe ASTRUM-005 trial (NCT04063163) revealed that combination serplulimab plus chemotherapy (etoposide and carboplatin [EC]) treatment was associated with survival advantages relative to chemotherapy alone in patients diagnosed with extensive-stage small-cell lung cancer (ES-SCLC). As the...

Full description

Bibliographic Details
Main Authors: Youwen Zhu, Kun Liu, Qun Qin, Hong Zhu
Format: Article
Language:English
Published: Frontiers Media S.A. 2023-01-01
Series:Frontiers in Immunology
Subjects:
extensive-stage small-cell lung cancer
serplulimab
etoposide and carboplatin
quality-adjusted life-years
incremental cost-effectiveness ratios
Online Access:https://www.frontiersin.org/articles/10.3389/fimmu.2022.1044678/full

Internet

https://www.frontiersin.org/articles/10.3389/fimmu.2022.1044678/full

Similar Items